阻害性多動性心筋病に対するアフィカムテンまたはメトプロロール単独療法
Pablo Garcia-Pavia1,2, Martin S Maron3, Ahmad Masri4
1Hospital Universitario Puerta de Hierro de Majadahonda, Instituto Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERCV), Madrid.
The New England journal of medicine
|September 1, 2025
まとめ
メトプロロールと比較して,アフィカムテン単独治療は,阻害性多動性心筋病 (HCM) の患者の運動能力を有意に改善し,症状を軽減しました. この心臓ミオシン阻害剤はHCMの優れた治療法です.
科学分野:
- 心臓病科
- 薬理学について
- 臨床試験
背景:
- 阻害性多動性心筋病 (HCM) はしばしばβ阻害剤で治療されますが,その有効性の証拠は限られています.
- 心臓のミオシン阻害剤であるAficamtenは,標準的な薬剤と併用すると,HCMの症状と運動能力の改善に有望であることが示されています.
研究 の 目的:
- 症状のある阻害性HCMの患者におけるアフィカメン単独治療とメトプロロール単独治療の有効性を比較する.
- 運動能力,機能的状態,および血液動力学的パラメータに対するアフィクメンの影響を評価する.
主な方法:
- 国際的な,ダブルブラインド,ダブルダミー試験では,症状のある阻害性HCMを患った175人の成人をランダムにアフィクメンまたはメトプロロールで投与しました.
- 主なエンドポイントは24週間のピーク酸素摂取の変化でした. 二次評価項目は,NYHA機能クラス,KCCQ-CSS,および血液動力学的測定値の改善でした.
主要な成果:
- メトプロロールと比較して,アフィカムテン単独療法でピーク酸素吸収が著しく増加しました (2. 3 ml/ kg/ minの差,P< 0. 001).
- aficamtenを投与された患者は,NYHAクラス,KCCQ-CSS,左心室出血管グラデント,NT-proBNP,そして左心房体積指数においてより大きな改善を示した.
- アフィカメンとメトプロロール群の副作用は類似した.
結論:
- 症状のある阻害性HCMにおける運動能力と血液動力学の改善には,メトプロロール単独療法より優れている.
- Aficamtenは,HCM患者の症状の軽減と生活の質の改善において,臨床的に有意義な効果を示しています.
関連する概念動画
01:29Cardiomyopathy V: Interprofessional Care
32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45
01:22Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
253
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
253